A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL).

Trial Profile

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Eltrombopag (Primary) ; Vorinostat (Primary)
  • Indications Cutaneous T cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Adverse reactions
  • Acronyms VEIL
  • Most Recent Events

    • 03 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Oct 2012 Planned End Date changed from 1 Jul 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top